Shots:

• The P-III ORIENT-3 trial involves assessing the efficacy and safety of Tyvyt (sintilimab) vs docetaxel (q3w) in 290 patients in a ratio (1:1) as a 2L treatment for advanced or m-sqNSCLC
• The trial met its 1EP i.e improvement in OS- mOS (11.79 vs 8.25 mos.)- mPFS (4.30 vs 2.79 mos.)- ORR (25.5% vs 2.2%)- safety was consistent with previous studies- and no new safety signals were identified
• Currently- NMPA has three Tyvyt’s sNDA under review which include sNDA for 1L therapy in squamous NSCLC- 1L therapy in HCC- and 2L therapy in sqNSCLC

  Ref: PRNewswire | Image:Innovent